Anavex Life Sciences Corp (AVXL)

[JB3729]

Whatever the reason for the run-up, here's what we learned: At 31 weeks, 27 of 32 patients remained on therapy, and the cognitive abilities of all patients, as measured by the mini-mental state examination (MMSE), were slightly lower at 31 weeks than they were at the beginning.

The author failed to mention that the dosing was not optimized. The doses given were 10mg - 50mg. If he was going to show a graph and comment on that graph, the least he could have done is include that.

From Anavex -

However, this analysis was based on pooled data from a relatively small number of subjects receiving a variety of doses. It is therefore unlikely that these findings reflect the full potential ANAVEX 2-73 in treating Alzheimer’s disease. It is unreasonable to draw conclusions about any limits to the long-term efficacy of ANAVEX 2-73 based on the interim Phase 2a findings, especially since no statistically significant decline from baseline was reported, which is impressive.

Of course, the author wouldn't want readers to know this. His purpose for writing the article was to attack Anavex and prompt readers to draw conclusions.